Search XBIO
Xenetic Biosciences, Inc.
Nasdaq · CIK 1534525
Last close2.24
Daily change+0.00 (0.00%)
10 Years gain-99.59%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
XBIO · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
80.9Momentum
100.0Acceleration
100.0Confidence
78.0Annual Revenue17
Quarterly Revenue38
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth21.9 / 25
Quality16.4 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics3.5 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 76.6379 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 48.778%.
Key Metrics
Revenue Growth TTM26.16%OK
Revenue CAGR 3Y20.36%OK
Gross Margin100%OK
Operating Margin-88.93%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y247.75%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y48.78%OK
SBC / Revenue3.07%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $2.98M | $2.98M | -$2.83M | -$2.29M | n/a | 100% | -95.23% | n/a | n/a | 1.7M |
| 2025 FY Dec 31, 2024 | $2.50M | $2.50M | -$4.20M | -$2.82M | n/a | 100% | -168.16% | n/a | -1,015.43% | 1.54M |
| 2024 FY Dec 31, 2023 | $2.54M | $2.54M | -$4.52M | -$4.11M | n/a | 100% | -177.79% | n/a | -523.67% | 1.53M |
| 2023 FY Dec 31, 2022 | $1.71M | $1.71M | -$6.72M | -$4.65M | n/a | 100% | -393.57% | n/a | -1,516.12% | 1.42M |
| 2022 FY Dec 31, 2021 | $1.16M | $1.16M | -$5.75M | -$4.74M | n/a | 100% | -495.12% | n/a | -1,083.26% | 10.28M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $3.08M | sum latest 4 fiscal quarters Revenue | OK | 0001683168-26-006061, 0001683168-25-008259 |
| Revenue Growth TTM | 26.16% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001683168-26-006061, 0001683168-25-008259 |
| Revenue CAGR 3Y | 20.36% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001683168-26-001737 |
| Revenue CAGR 5Y | 46.78% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001683168-26-001737 |
| Gross Profit CAGR 3Y | 20.36% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001683168-26-001737 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001683168-26-006061, 0001683168-25-008259 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001683168-26-006061, 0001683168-25-008259 |
| Operating Margin | -88.93% | Operating Income / Revenue | OK | 0001683168-26-006061, 0001683168-25-008259 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001683168-26-006061 |
| Current Ratio | 7.43x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 3.07% | SBC / Revenue | OK | 0001683168-26-006061, 0001683168-25-008259 |
| Revenue per Diluted Share | $1.34 | Revenue / Diluted Shares | OK | 0001683168-26-006061, 0001683168-25-008259 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | 0001683168-26-006061, 0001683168-25-008259 |